Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review.

Publisher: SAGE Publications Country of Publication: England NLM ID: 9610930 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0377 (Electronic) Linking ISSN: 1358863X NLM ISO Abbreviation: Vasc Med Subsets: MEDLINE

Publication: London : SAGE Publications
Original Publication: London, UK : Letchworth, Hertfordshire, UK : Arnold ; Turpin Distribution Services, c1996-

Cardiovascular Diseases*/diagnosis ; Cardiovascular Diseases*/drug therapy ; Cardiovascular Diseases*/prevention & control ; Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/diagnosis ; Diabetes Mellitus, Type 2*/drug therapy ; Peripheral Arterial Disease*/diagnosis ; Peripheral Arterial Disease*/drug therapy ; Peripheral Arterial Disease*/chemically induced ; Sodium-Glucose Transporter 2 Inhibitors*/adverse effects; Humans ; Canagliflozin/therapeutic use ; Hypoglycemic Agents/adverse effects

Peripheral artery disease (PAD) and diabetes mellitus are two overwhelming health problems associated with major cardiovascular (CV) and limb events, in addition to increased mortality, despite advances in medical therapies including statins and renin-angiotensin system inhibitors. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1-receptor agonists (GLP1-RA) are two new antihyperglycemic drug classes that have been associated with a significant reduction of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) and CV risk. Whereas most studies had enrolled patients with T2D and concurrent CV disease (CVD), patients with PAD were obviously underrepresented. Furthermore, there was a signal of increased risk of amputation in one of the main trials with canagliflozin. We aim to provide a general review of the current literature and summarize societal guideline recommendations addressing the role of SGLT2i and GLP1-RA drugs in patients with CVD focusing on the PAD population when data are available. Endpoints of interest were MACE and, when available, major adverse limb events (MALE).

Keywords: GLP1-RA; SGLT2i; diabetes mellitus; peripheral artery disease (PAD)

0SAC974Z85 (Canagliflozin)
0 (Hypoglycemic Agents)
0 (Sodium-Glucose Transporter 2 Inhibitors)
0 (SLC5A2 protein, human)
0 (GLP1R protein, human)

Date Created: 20230103 Date Completed: 20230214 Latest Revision: 20230306

20230307

10.1177/1358863X221143811

36593757